- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07562438
Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
Prospective Clinical Trial of Low-dose 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) has demonstrated promising potential for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Conjugation of albumin-binding moieties to PSMA-targeted radioligands can prolong their circulating half-life in the blood, thereby markedly enhancing tumor uptake and therapeutic efficacy. P17-088 incorporates a pegylated p-iodophenylbutanoyl group as an albumin binder with moderate binding affinity yet superior overall performance, which achieves a refined balance between augmented tumor accumulation and favorable safety profiles.
In our preliminary first-in-human study, 177Lu-P17-088 was observed to exhibit elevated distribution in organs including the red bone marrow and kidneys, with a considerably higher accumulation magnitude in tumor lesions. Satisfactory therapeutic outcomes were achieved even at a low activity dose of 1.11 GBq, validating its potential for further clinical translational research.
This single-arm study is designed to further evaluate the safety and efficacy of low-dose 177Lu-P17-088 in mCRPC patients. 177Lu-P17-088 will be administered at a fixed activity of 3.7 GBq (±10%) once every 6 to 8 weeks, with a total of four planned treatment cycles.
Post-treatment follow-up (safety and efficacy): Upon discontinuation of treatment, all enrolled participants will undergo systematic safety surveillance, including a 30-day short-term safety follow-up (FUP) assessment and extended long-term safety monitoring for approximately 12 months.
Survival follow-up: Following the termination of study treatment or completion of the post-treatment follow-up period, participants' vital status will be collected via telephone contact every 90 days as part of survival surveillance. Strict adherence to the survival follow-up schedule shall be ensured to facilitate complete survival data acquisition. Survival follow-up and the overall study will be concluded once the required number of overall survival (OS) events for the final survival analysis is reached.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Weibing Miao, MD
- Numéro de téléphone: +86-0591-87981618
- E-mail: miaoweibing@126.com
Sauvegarde des contacts de l'étude
- Nom: Guochang Wang, MD
- Numéro de téléphone: +86-0591-87981619
- E-mail: guochang1007@163.com
Lieux d'étude
-
-
Fujian
-
Fuzhou, Fujian, Chine, 350005
- Recrutement
- Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
-
Contact:
- Guochang Wang, MD
- Numéro de téléphone: +86-0591 87981619
- E-mail: guochang1007@163.com
-
Contact:
- Jie Zang, MD
- Numéro de téléphone: +86-0591 87981619
- E-mail: 15901495106@163.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
Metastatic Castration-Resistant Prostate Cancer (mCRPC) mCRPC refers to prostate cancer that progresses despite serum testosterone at castrate levels (< 50 ng/dL or 1.7 nmol/L), meeting at least one of the following criteria:
- PSA >1 ng/mL with two consecutive rises at least 1 week apart, each increase ≥ 50% above the nadir.
- Radiographic progression: Either two or more new bone lesions on bone scan, or soft tissue lesion progression as per RECIST 1.1 criteria. Progression based on symptoms alone is insufficient for mCRPC diagnosis and requires further evaluation.
Failure of, Refusal of, Absence of, or Refractoriness to Standard Therapy, or Disease Progression, or No Available Standard Therapy per Current Guidelines:
- Patients who have not received, refused, or progressed after receiving at least 1 but no more than 2 prior taxane-based therapies. The taxane regimen must have included exposure for at least 2 cycles. Patients who received only one taxane may be included if the investigator deems them unsuitable for a second taxane (e.g., due to frailty assessed by geriatric/comorbidity evaluation or intolerance).
- Patients who have progressed after receiving at least one novel androgen axis drug [NAAD] (e.g., abiraterone, enzalutamide).
- Ability to understand and voluntarily sign a written informed consent form (ICF), and willingness and ability to comply with trial procedures including examinations and follow-up.
- Age 18-90 years (inclusive).
- Expected survival > 6 months.
- ECOG performance status ≤ 2.
- Presence of high-uptake lesions confirmed by 68Ga-PSMA-11 PET/CT imaging (positive defined as lesion uptake >1.5 times the liver background).
- At least one measurable lesion per RECIST 1.1 criteria OR at least one bone metastasis per PCWG3 criteria.
Adequate organ function (No blood products, growth factors, or albumin administered within 14 days prior to baseline lab tests):
- Bone Marrow Function: Neutrophil count ≥ 1.5 × 10#/L, White blood cell count ≥ 3.0 × 10^9/L, Platelet count ≥ 100 × 10^9/L, Hemoglobin ≥ 10 g/dL (≥ 100 g/L).
- Liver Function: Albumin ≥ 30 g/L, Total bilirubin ≤ 1.5 × ULN, ALT or AST ≤ 3.0 × ULN (without liver metastases) or ≤ 5.0 × ULN (with liver metastases).
- Renal Function: Serum creatinine ≤ 1.5 × ULN.
- Agreement to comply with prescribed radiation protection measures during the trial period.
Exclusion Criteria:
- Inability to tolerate imaging procedures;
- Patients who have received systemic anticancer therapy (e.g., chemotherapy, radiotherapy, immunotherapy; excluding endocrine therapy), investigational drugs, or device therapy within 4 weeks prior to dosing;
- Patients who received radionuclide therapy (Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, Lutetium-177) within 6 months, or any External Beam Radiation Therapy (EBRT) within 2 months prior to the first dose;
- Patients with unresolved Grade 4 myelosuppression from prior anticancer therapy within 2 weeks, or Grade 3 myelosuppression requiring >6 weeks for recovery;
- Planned use of cytotoxic chemotherapy, antitumor immunotherapy, radioligand therapy, or similar agents during the study;
- Use of blood products or albumin within 14 days before dosing to meet enrollment criteria;
Brain metastasis at screening, except:
- Asymptomatic cases confined to supratentorial/cerebellar regions (no midbrain/pons/medulla/spinal cord involvement) without corticosteroid therapy and with lesions ≤1.5 cm;
- Symptomatic cases with treated and radiologically stable lesions (>4 weeks);
- Other malignancies within 5 years (excluding cured localized cancers like basal/squamous cell skin carcinoma);
- Superscan on bone scintigraphy;
- Symptomatic or impending spinal cord compression;
- Prior EBRT involving extensive bone marrow (>25%);
Significant cardiac disease at screening, including:
- QTcF >470 ms or long QT syndrome history;
- Myocardial infarction, angina, or CABG within 6 months deemed ineligible by investigators;
- Any condition that, per investigator judgment, may compromise safety, data interpretation, or indicate high risk;
- Uncontrolled bladder outlet obstruction, urinary incontinence, claustrophobia, or radiophobia at screening;
- Positive for HCV-Ab, HIV, or syphilis antibodies at screening;
- HBsAg-positive patients with active HBV replication (confirmed by HBVDNA per investigator assessment);
- Known allergy to proteins/peptides, excipients, or structurally related compounds;
- History of drug/alcohol abuse within 1 year or chronic substance abuse;
- Failure to use effective contraception during the trial and for 6 months post-last dose;
- Severe active infection prior to the first administration.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: 177Lu-P17-088
Participant will receive 3.7 GBq (+/- 10%) 177Lu-P17-088, once every 6-8 weeks for a planned 4 cycles
|
administered intravenously once every 6-8 weeks (1 cycle) for 4 cycles
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Réponse de l'antigène spécifique de la prostate (PSA50)
Délai: De la date de la randomisation à 30 jours de sécurité FUP, évaluée jusqu'à 50 mois (analyse estimée du système d'exploitation final)
|
La réponse du PSA50 est définie comme la proportion de patients qui ont une diminution plus / égale de 50% du PSA par rapport à la ligne de base, il sera calculé à 12, 24 et 48 mois
|
De la date de la randomisation à 30 jours de sécurité FUP, évaluée jusqu'à 50 mois (analyse estimée du système d'exploitation final)
|
|
Nombre de participants avec des événements indésirables émergents du traitement
Délai: De l'inscription à 30 jours de suivi de la sécurité, évalué jusqu'à 50 mois (analyse estimée du système d'exploitation final)
|
La distribution des événements indésirables (AE) se fera via l'analyse des fréquences pour le traitement émergent émergent (TEAES), l'événement indésirable grave (TESAE) et les décès dus aux EI, par le biais de la surveillance des paramètres de sécurité cliniques et de laboratoire pertinents.
|
De l'inscription à 30 jours de suivi de la sécurité, évalué jusqu'à 50 mois (analyse estimée du système d'exploitation final)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression Free Survival (PFS)
Délai: From date of enrollment until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)
|
PSA-PFS is defined as the time from date of enrollment to the date of first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) or death from any cause, whichever occurs first.
|
From date of enrollment until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)
|
|
Overall Survival (OS)
Délai: From date of enrollment until date of death from any cause, assessed up to 50 months (estimated final OS analysis)
|
OS is defined as time to death for any cause.
|
From date of enrollment until date of death from any cause, assessed up to 50 months (estimated final OS analysis)
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Temps de réponse (TTR)
Délai: De la date d'inscription à 30 jours de sécurité FUP, évaluée jusqu'à 50 mois (analyse estimée du système d'exploitation final)
|
TTR est défini comme l'heure de la date d'inscription à la date de la première réponse documentée (CR ou PR).
|
De la date d'inscription à 30 jours de sécurité FUP, évaluée jusqu'à 50 mois (analyse estimée du système d'exploitation final)
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chaise d'étude: Weibing Miao, MD, Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- FirstAHFujian-177Lu-P17-088
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .